Cereno Scientific Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Sten Sorensen

Chief executive officer

kr7.3m

Total compensation

CEO salary percentage	38.0%
CEO tenure	9.3yrs
CEO ownership	n/a
Management average tenure	1.4yrs
Board average tenure	less than a year

Recent management updates

Recent updates

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

Sep 01

We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Apr 05

CEO Compensation Analysis

How has Sten Sorensen's remuneration changed compared to Cereno Scientific's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr7m	kr3m	-kr48m
Sep 30 2023	n/a	n/a	-kr35m
Jun 30 2023	n/a	n/a	-kr31m
Mar 31 2023	n/a	n/a	-kr27m
Dec 31 2022	kr2m	kr2m	-kr28m

Compensation vs Market: Sten's total compensation ($USD686.06K) is above average for companies of similar size in the Swedish market ($USD252.64K).

Compensation vs Earnings: Sten's compensation has increased whilst the company is unprofitable.

CEO

Sten Sorensen (64 yo)

9.3yrs

Tenure

kr7,347,000

Compensation

Mr. Sten R. Sorensen serves as Director of Cereno Scientific AB (publ) since April 16, 2024. He serves as Director of SynAct Pharma AB since March 20, 2024. He serves as the Chief Executive Officer at Cere...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sten Sorensen	CEO & Director	9.3yrs	kr7.35m	no data
Jonas Saljo	Chief Intellectual Property Officer	4.9yrs	kr893.00k	no data
Eva Jagenheim	Chief Financial Officer	less than a year	no data	no data
Bjorn Dahlof	Chief Scientific Officer	1.4yrs	kr96.00k	0.27% SEK 2.8m
Henrik Westdahl	Director of Communications & IR	less than a year	no data	no data
Tove Bergenholt	Director of Communications & IR (currently on parental leave)	less than a year	no data	no data
Fredrik Frick	Head of Clinical Operations	2yrs	no data	no data
Nicholas Oakes	Head of Preclinical Development	1.8yrs	no data	no data
Rahul Agrawal	Chief Medical Officer & Head of R&D	less than a year	no data	no data

1.4yrs

Average Tenure

57yo

Average Age

Experienced Management: CRNO B's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Sten Sorensen	CEO & Director	less than a year	kr7.35m	no data
Bertram Pitt	Chairman of Scientific Advisory Board	no data	no data	no data
Deepak Bhatt	Member of Scientific Advisory Board	no data	no data	no data
Jeppe Ovlesen	Director	less than a year	kr18.00k	no data
Gordon Williams	Member of Scientific Advisory Board	no data	no data	no data
Anders Svensson	Director	5.6yrs	kr917.00k	0.13% SEK 1.4m
Gunnar Olsson	Director & Member of Scientific Advisory Board	less than a year	no data	no data
Raymond Benza	Member of Scientific Advisory Board	3.3yrs	no data	no data
Faiez Zannad	Member of Scientific Advisory Board	no data	no data	no data
Joakim Soderstrom	Chairperson	1.3yrs	kr2.61m	0.55% SEK 5.6m

0.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: CRNO B's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.

Cereno Scientific Management

Management criteria checks 0/4

Key information

Recent management updates

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Director exercised options to buy kr1.0m worth of stock.

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Recent updates

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Director exercised options to buy kr1.0m worth of stock.

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024

Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting

Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585

Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study

Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family

Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH

New major risk - Financial position

Third quarter 2023 earnings released

Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH

Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member

Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH)

Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024

New major risk - Shareholder dilution

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

Chief Medical Officer recently bought kr208k worth of stock

Second quarter 2023 earnings released

Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah

Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer

Cereno Scientific Reports Positive Data from Patient Case Study

Chairperson recently bought kr804k worth of stock

Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH

Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024

Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH

Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1

Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021)

We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021)

Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension

Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023

Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023

Cereno Scientific Announces Changes in the Executive Management Team

Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr0.069 loss per share (vs kr0.047 loss in 3Q 2021)

No independent directors

Cereno Scientific's Patent Protection for Drug Candidate CS1 Expands in Mexico Through Its Second Patent Family

Cereno Scientific Reports First Patient Dosed in Phase II Study in PAH with Drug Candidate CS1

Second quarter 2022 earnings released

Cereno Scientific's Innovative Phase II Study Design in PAH with CS1 is Accepted for Presentation at the CHEST Annual Meeting on Oct. 16-19 in Nashville, US

Cereno Scientific Announces Enrolling the First Patient in Its Phase II Clinical Study with Lead Drug Candidate Cs1 in Pulmonary Arterial Hypertension

Cereno Scientific Reports First Patient Enrolled in Phase II Study in PAH with Drug Candidate CS1

Frejs Revisorer AB Announces Board Appointments

Cereno Scientific AB Appoints Nick Oakes as Head of Preclinical Development

Cereno Scientific AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

First quarter 2022 earnings released

Cereno Scientific's Abstract on CS1's Innovative Phase II Study Design Accepted At Top Pulmonary Vascular Congress PVRI Held in June, 2022

Cereno Scientific to Present Candidate Drug CS585 Preclinical Data At EHA 2022 - the Premier Medical Congress for Hematology

Cereno Scientific Nominates Drug Candidate CS585 in PCA Program for Continued Development in Cardiovascular Disease

No independent directors

Full year 2021 earnings released: kr0.15 loss per share (vs kr0.22 loss in FY 2020)